Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This randomized controled open label clinical trial conducted in patients with hypoxemic
respiratory failure admitted to the ICU and requiring ventilatory support (invasive or
non-invasive) is to evaluate whether treatment with cyproheptadine, a serotonin receptor
antagonist, compared to usual care, increases the number of ventilator-free days.